In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Active Biotech AB

Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024

Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.

Financing Business Strategies

Finance Watch: More Good To Come? CG Oncology Grosses $380m In Year’s First IPO

Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively. 

Financing Business Strategies

Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024

Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.

Commercial Companies

Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

Companies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register